Eyenovia Partners
Strategic Partnerships to Potentially Extend Commercial Reach
Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products Learn more.Â
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health organization with core businesses in over the counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in ophthalmology. Bausch is a leading global eye health company that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Learn more.
Senju is a leading specialty pharmaceutical company in Asia with strong experience in developing and commercializing novel ophthalmic drugs. The company produces prescription drugs, over the counter medicines, animal drugs, and other products. Senju Pharmaceutical also produces eye drops, contact lens cleaners, and other products. Since Senju was established in 1947, they have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through unique ideas and R&D capabilities. Learn more.Â
Future Licensing Opportunities
Our microdose array print technology, delivered with the Optejet® dispenser, is covered by multiple domestic and international patents. We believe our technology platform improves the therapeutic profile of drug solutions – new and existing.
If your medication could benefit from any of the features that our technology makes possible, please contact us for an introductory discussion. Some of these features may include:
- Improved ease-of-use, especially in populations where using eye drops may be difficult
- Improved therapeutic index, maintaining efficacy while potentially reducing topical and systemic side effects
- Improved tolerability, especially with formulations at very low or high pH
- Preserved, minimally preserved, or non-preserved formulations
- Improved compliance and adherence, with smart technology paired to smart phones for reminders and tracking usage